Spyre Therapeutics

SYRE

----

Current ValuationThe current P/E ratio is -44.30, within the reasonable range, cheaper than 55.56% of the time in the past 1 years, and the industry ranks 536/605, the industry Median -1.82.

-44.3xP/E

Stock price$104.48Earnings per share$-2.36

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

013263952

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
GILDUSGilead Sciences	-54.88x	162.77%	$211.94B
MRNAUSModerna	-35.91x	3.57%	$100.14B
CSLLYUSCSL Limited	-25.59x	--	$65.99B
NTRAUSNatera	-274.65x	0.76%	$45.24B
RVMDUSRevolution Medicines	-22.12x	40.80%	$41.38B
ROIVUSRoivant Sciences	-86.40x	85.66%	$29.75B
INSMUSInsmed	-43.28x	74.47%	$26.21B
BNTXUSBioNTech SE	-12.78x	24.44%	$21.62B
BBIOUSBridgebio Pharma	-25.88x	30.83%	$15.32B
SMMTUSSummit Therapeutics	-17.08x	23.12%	$14.22B
KYMRUSKymera Therapeutics	-32.52x	8.74%	$11.36B
BMRNUSBioMarin Pharma	-578.91x	61.50%	$11.07B
PCVXUSVaxcyte	-9.15x	44.27%	$10.50B
MDGLUSMadrigal Pharma	-64.64x	87.15%	$10.05B
SYREUSSpyre Therapeutics	-44.30x	59.92%	$9.92B
PRAXUSPraxis Precision Medicines	-26.22x	3.20%	$9.43B
TWSTUSTwist Bioscience	-63.62x	28.63%	$8.70B
RYTMUSRhythm Pharma	-39.84x	51.65%	$7.90B
CYTKUSCytokinetics	-10.06x	8.47%	$7.83B
ALKSUSAlkermes	-22,247.82x	133.59%	$7.81B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.